Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04026412 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 925
- Enrollment target
- 20
- Study locations
NCT04026412 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 925 participants, above the 273-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (239% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT04026412, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 925 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
Conditions Studied
Interventions
- BIOLOGICAL nivolumab
- BIOLOGICAL durvalumab
- BIOLOGICAL ipilimumab
Study Locations (20)
Ohio
- Local Institution - 0053 - Cincinnati
- Local Institution - 0131 - Cincinnati
- Local Institution - 0188 - Cincinnati
- Local Institution - 0112 - Cleveland
- Local Institution - 0124 - Cleveland
- Local Institution - 0047 - Cleveland
- Local Institution - 0123 - Youngstown
California
- Local Institution - 0119 - La Jolla
- Local Institution - 0207 - San Francisco
- Local Institution - 0166 - San Francisco
Florida
- Local Institution - 0233 - Jacksonville
- Local Institution - 0219 - Orlando
- Local Institution - 0039 - Pensacola
Georgia
- Local Institution - 0125 - Atlanta
- Local Institution - 0165 - Augusta
Colorado
- Local Institution - 0129 - Lone Tree
Kentucky
- Local Institution - 0218 - Edgewood
Maryland
- Local Institution - 0108 - Bethesda
Michigan
- Local Institution - 0116 - Traverse City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 925 participants |
| Start Date | 2019-10-08 |
| Est. Completion | 2024-11-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04026412
The ClinicalTrials.gov registry entry for NCT04026412 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 925 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 273-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (239% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 3 interventions - of which nivolumab is the first listed.
NCT04026412 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Ohio, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04026412 about?
NCT04026412 is a clinical study titled "A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery". The primary purpose of the study is to compare the effectiveness of nivolumab plus concurrent chemoradiotherapy (CCRT) followed by nivolumab plus ipilimumab vs CCRT followed by durvalumab in participants with untreated Locally Advanced Non-small Cell Lung Cancer (LA NSCLC).
What is the current status of trial NCT04026412?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 925 participants. The study started on 2019-10-08. Estimated completion is 2024-11-26.
What conditions does trial NCT04026412 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT04026412?
The interventions under investigation include: nivolumab (BIOLOGICAL), durvalumab (BIOLOGICAL), ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04026412?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04026412 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
RECRUITING · Phase 3
-
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
RECRUITING · Phase 3
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.